Parity status and the relationship between antenatal rubella serology with obstetric outcome

Terence T. Lao, Shuk Yi Annie Hui & Daljit S. Sahota

Routine antenatal rubella serological testing is adopted in many countries. In a population covered by universal childhood rubella immunization for four decades, we have observed an association between pre-eclampsia with maternal rubella seronegativity among multiparous gravidae. This retrospective cohort study was further performed to elucidate the interaction between parity status and rubella seronegativity on obstetric outcome in singleton pregnancies carried to ≥ 24 weeks gestation managed from 1997 to 2019, with the data retrieved from a computerized database used for annual statistics and auditing. Of the 133,926 singleton pregnancies eligible for the study, the 13,320 (9.9%) rubella seronegative gravidae had higher mean booking weight and body mass index (BMI), but shorter height, and higher incidence of advanced age (≥ 35 years), high BMI, short stature, and lower incidence of nulliparas. Univariate analysis showed that adverse obstetric outcomes were more frequently found among the multiparas. On multivariate analysis, there was increased postdated (> 41 weeks) pregnancy irrespective of parity status, while nulliparas had reduced gestational hypertension (aRR 0.714, 95% CI 0.567–0.899) and gestational diabetes (aRR 0.850, 95% CI 0.762–0.950), and multiparas had increased pre-eclampsia (aRR 1.261, 95% CI 1.005–1.582), neonatal death (aRR 2.796, 95% CI 1.243–6.291), and perinatal death (aRR 2.123, 95% CI 1.257–3.587). In conclusion, in a population covered by universal childhood rubella immunization, antenatal rubella seronegativity is associated with increased pre-eclampsia and perinatal loss only in multiparas, suggesting that the rubella seronegativity in these women served as proxy for some form of altered immune response which increases adverse pregnancy outcome.

With the introduction of the live-attenuated rubella vaccine to prevent congenital rubella syndrome, the rate of rubella sero-negativity at antenatal screening has been reduced to < 5% in developed countries such as Finland, Australia, USA and Taiwan. Nevertheless, it was also shown that the overall seronegative rate in women aged 15–39 years in European countries which have adopted universal immunization remained variable from 1.4% in the Czech Republic to 13.4% in Belgium. While there might be a number of different reasons to explain the variable incidence of rubella sero-negativity in the aforementioned European countries, one underlying cause could have been vaccine non-response in some of the seronegative women.

In Hong Kong, rubella immunization was introduced in 1978, which evolved to the current two-dose mumps-measles-rubella (MMR) vaccination regimen at 12 months and 12 years of age from 1996 with 99% coverage of all primary six students, together with catch-up vaccination provided to susceptible women of reproductive age as well as postnatal immunization to seronegative gravidae. Despite the rigorous implementation of rubella immunization, antenatal screening revealed that 8.1% of the gravidae were seronegative, a situation similar to the findings in Europe. However, whether antenatal rubella sero-negativity within an obstetric population covered by universal childhood immunization has implications on pregnancy outcome remains unclear, owing to the scanty literature on the subject. A case–control study which examined the obstetric outcome by rubella immunity status found no difference in adverse outcome between 285 cases with rubella IgG < 10 IU/ml and 285 controls. However, the study was probably underpowered, as the incidence of pre-eclampsia (PE) in the cases was 3.5% which was almost 50% higher than the 2.4% in the controls. On the other hand, we have found that rubella seronegative status was associated with increased PE among multiparous but not nulliparous gravidae, suggesting that rubella sero-negativity in our population could be a surrogate for subtle differences in maternal immune status which could predispose towards PE. It is known that maternal tolerance of the foetal-placental unit in a successful pregnancy involves a shift to a distinct
Th2 bias with decreased Th1 cytokines that begins from the first trimester to peak in the third trimester\textsuperscript{13,14}, and the immunologic status changes to a pro-inflammatory phase in the first trimester, an anti-inflammatory phase in subsequent trimesters, and finally returning to a renewed inflammatory phase at parturition\textsuperscript{15}. Indeed, different maternal cytokine profiles were found to associate with pregnancy complications\textsuperscript{16}, and whether rubella sero-negativity among vaccinated women could be proxy to some form of underlying differences in maternal immunological status remains an unanswered question. We therefore performed this retrospective cohort study to compare obstetric outcomes between rubella seronegative with seropositive gravidae to determine if rubella immunity status has any bearing on pregnancy outcome in addition to the influence on PE as reported before\textsuperscript{12}.

Materials and methods

Our hospital is a public regional tertiary referral centre catering for a population of 1.7 million, currently with an annual delivery rate of around 7000 which consisted almost entirely of public patients. Routine antenatal screening for rubella IgG antibody titre by EIA (AxSYM, Abbott) is performed at the first antenatal attendance. The test is performed by the accredited central laboratory under the Department of Health (DH) if the antenatal booking visit occurs at the maternal and child health centres (MCHC), and in the accredited hospital pathology laboratory if the booking visit occurs at the hospital. Women with a titre of \( \geq 10\) IU/ml are reported as immune, while seronegative women with antibody titre \(< 10\) IU/ml are reported as non-immune, but the actual titre is not provided in the report. Women seronegative for rubella are referred after delivery for rubella vaccination at the MCHC where their babies will also receive the rest of the immunization program for infancy. However, details of postpartum rubella vaccination were not available as we could not access the postnatal management and vaccination data from DH statistics. Antenatal screening results, clinical information, and medical intervention, and obstetric outcome, are all entered into our computerized patient record and the database is used for both clinical management and generation of annual statistics for our Hospital Authority.

In this retrospective study, we categorized gravidae carrying a singleton pregnancy to beyond 24 weeks gestation and delivering in our hospital between 1997 and 2019 by their rubella serology status for comparison of maternal characteristics and pregnancy outcome. Maternal characteristics included established obstetric risk factors and medical history\textsuperscript{14,15}, and specific obstetric risk factors included nulliparous status and advanced \((\geq 35\) years) age\textsuperscript{18,19}, body mass index (BMI) at booking and incidence of high \((>25\) kg/m\(^2\)) BMI, height and incidence of short stature defined as height at or less than the 25th percentile of our obstetric population which has influence on the occurrence of pregnancy hypertensive disorders\textsuperscript{19}, history of abortion which, inclusive of both spontaneous and induced as well as just one or recurrent abortions, is an usually overlooked risk factor which impacts on subsequent pregnancy outcome including the development of pregnancy hypertensive disorders\textsuperscript{20–26}, and carried a male foetus\textsuperscript{27}. Pregnancy outcome analysed included gestational hypertension (GH), PE, gestational diabetes (GDM), placenta praevia, placental abruption, preterm birth \((< 37\) weeks), post-dated pregnancy \((\text{carried to beyond } 41\text{ weeks gestation})\), labour induction, caesarean section \((\text{CS})\), manual removal of placenta \((\text{MRP})\), postpartum haemorrhage \((\text{PPH})\), infant gender, infant macrosomia \((\text{birthweight } \geq 4000\) g\)), low birthweight infants \((\text{birthweight } < 2500\) g\)), Apgar score at 5th minute \(< 7\) as an indication of asphyxia, and total perinatal death, and stillbirth and neonatal death. The diagnosis of PE was made according to the International Society for the Study of Hypertension in Pregnancy criteria\textsuperscript{28}. As pregnancy-induced hypertension in the literature sometimes included both hypertension with and without proteinuria, we avoided any confusion by separating women with hypertension diagnosed after 20 weeks gestation without proteinuria (including those with unknown blood pressure before 20 weeks of gestation) as GH; while PE referred to hypertension with significant proteinuria, including women with PE superimposed on pre-existing hypertension, so that these groups which are distinct entities\textsuperscript{29} did not overlap since the diagnosis was finalised at delivery. With the exception of maternal characteristics, all of whom were before term, specifically all the pregnancies had the gestational age confirmed by early foetal ultrasoundography performed to establish the gestational age in gravidae with uncertain dates, or irregular or prolonged menstrual cycles, and for screening of fetal structural anomalies and chromosomal abnormalities such as trisomy 21, so that the gestational age captured in the obstetric database were confirmed, and post-dated pregnancies were defined as pregnancies carried to beyond 41 completed weeks. Owing to a rigorously organised foetal screening programme, pregnancies carrying foetuses with lethal or significant congenital and chromosomal anomalies were invariably detected before delivery, mostly before foetal viability \((24\text{ completed weeks of gestation})\). As therapeutic termination of pregnancy before 24 weeks gestation was and still is legal in Hong Kong, almost all of these pregnancies were terminated before foetal viability and therefore not captured in the obstetric database, which therefore does not include details of foetal anomalies. Further analysis was performed stratified by maternal parity status owing to the known influence of parity status on pregnancy outcome\textsuperscript{30}. Statistical analysis was performed using t test and chi square test and calculation of relative risk \((\text{RR})\) with \(95\%\) confidence intervals \((\text{CI})\). Finally, the independent association between rubella sero-negativity with the examined pregnancy outcomes was determined by multiple logistic regression analysis considering the relevant risk factors identified, with the results expressed in adjusted relative risk \((\text{aRR})\) and \(95\%\) confidence intervals \((\text{CI})\). Statistics analysis was performed using a commercial statistical package \((\text{PASW Statistics } 26.0, \text{SPSS Inc., Chicago, Il})\).

The study was approved by the Institutional Review Board (Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee, Reference Number CRE-2017 442), which has waived informed consent from the study subjects eligible for the study as requested in the submission for ethical approval by the authors (SYAH and DSS) because the study utilized an anonymized database spanning 23 years. All methods were performed in accordance with the relevant guidelines and regulations.
Ethics approval. The study has received ethics approval from the Institutional Body ([Joint Chinese University of Hong Kong—New Territories East Cluster Clinical Research Ethics Committee, Reference Number CRE-2017.442]).

Consent for publication. Given by all authors.

Results

There were 133,926 cases in the database which had satisfied the inclusion criteria, and rubella sero-negativity was found in 13,320 (9.9%) cases. Although there was no significant difference in the mean maternal age (Table 1), rubella seronegative gravidae had significantly higher mean booking weight and BMI but shorter height, and had higher incidence of advanced age (RR 1.162, 95% CI 1.128–1.197), high BMI (RR 1.244, 95% CI 1.208–1.280), short stature (RR 1.120, 95% CI 1.089–1.152), but lower incidence of nulliparous women (RR 0.919, 95% CI 0.902–0.937). The mean gestational age and birthweight were only very slightly but still significantly higher, but there was no difference in the incidence of male infants.

When the history and pregnancy outcome were compared, the rubella seronegative gravidae had significantly higher incidence of abortion history, previous CS among the multiparas, obstetric complications overall, PE, post-dated pregnancy, CS, MROP, macrosomic infants, and neonatal death (Table 2). On the other hand, they had significantly lower incidence of past medical history and pre-existing conditions overall, GH, labour induction, and PPH. The incidence of most of the individual medical conditions were very low so that only the important ones which are known risk factors for adverse pregnancy outcomes including chronic hypertension, pre-gestational diabetes, and autoimmune conditions, were further analysed, but no significant difference could be found between rubella seronegative and seropositive gravidae.

Owing to the significant difference between the two groups in the incidence of multiparous gravidae, past history and pregnancy outcome were further analysed stratified by parity status. Among nulliparous gravidae (Table 3), there was significantly higher incidence of abortion history, obstetric complications overall, post-dated pregnancy, and macrosomic infants, whereas there was lower incidence of medical history, GH, and labour induction.

Among multiparous gravidae (Table 4), there was lower incidence of medical history, but higher incidence of abortion history, PE, GDM, post-dated pregnancy, CS, macrosomic infants, male infants, low fifth minute Apgar score, overall perinatal mortality, stillbirth and neonatal death.

To determine the independent association between rubella seronegative status with the different pregnancy outcomes demonstrated in the univariate analysis, multiple logistic regression analysis was performed (Table 5). In Model One, the relationship with obstetric complications overall, GDM, GH and PE was examined with adjustment for advanced maternal age, high BMI, short stature, male foetus, previous abortion history, and the presence of medical history. For the entire cohort, rubella seronegative status was associated with reduced GDM and GH, but increased post-dated pregnancy. When analysis was confined to nulliparous gravidae, rubella seronegative status was associated with reduced GDM and GH, but increased post-dated pregnancy. When analysis was confined to multiparous gravidae, rubella seronegative status was associated with increased PE, post-dated pregnancy, perinatal death and neonatal death. The reasons for the increased perinatal and neonatal deaths in the rubella seronegative group could not be determined because the baby records were set up as separate from those of their mothers (often with their new given names) in the computer system and could not be captured in the obstetric database.

| Rubella status | Seronegative | Seropositive | p     |
|---------------|-------------|-------------|-------|
| Number (% of total) | 13,320 (9.9) | 120,606 (90.1) | -     |
| Age (years) | 30.6 ± 5.8 | 30.6 ± 5.4 | 0.943 |
| Age ≥ 35 years (%)* | 26.9 | 23.1 | < 0.001 |
| Height (cm) | 157.4 ± 5.5 | 158.1 ± 5.5 | < 0.001 |
| Height ≤ 154 cm (%)* | 29.4 | 26.2 | < 0.001 |
| Booking weight (kg) | 57.9 ± 9.5 | 56.9 ± 9.3 | < 0.001 |
| Booking BMI (kg/m²) | 23.4 ± 3.6 | 22.8 ± 3.5 | < 0.001 |
| BMI ≥ 25 kg/m² (%)* | 28.1 | 22.6 | < 0.001 |
| Nulliparous gravidae (%)* | 47.8 | 52.0 | < 0.001 |
| Gestational age (wks) | 38.9 ± 1.9 | 38.8 ± 1.8 | 0.016 |
| Birthweight (g) | 3182 ± 491 | 3152 ± 479 | < 0.001 |
| Male infant (%)* | 52.2 | 52.0 | 0.692 |

Table 1. Maternal and infant characteristics between gravidae seronegative versus seropositive for rubella immunity. BMI body mass index. Results expressed in mean ± SD and compared with the t test, or in % as indicated* and compared with the chi square test.
Discussion

The results of this study revealed that in a city where universal childhood rubella immunization has been implemented for more than four decades, pregnant women found to be rubella seronegative at routine antenatal screening exhibited slightly but significantly different characteristics. Specifically, there were more multiparous gravidae, which was contrary to expectation in view of the local government policy of repeated vaccination for postnatal women seronegative for rubella at routine antenatal screening. The slightly higher incidence of advanced age, short stature, and high BMI suggested that the different age distribution and anthropometric characteristics reflected underlying differences in health status, since women of both groups were from the same ethnic background, so that these women could have earlier waning of rubella immunity, or had a higher proportion of vaccine non-responders. Furthermore, there were significant differences in their past history and pregnancy outcomes, including both increased as well as reduced incidence of some specific outcomes. When analysis was stratified by parity status, nulliparous gravidae had increased post-dated pregnancy but reduced GH and GDM, and no increased adverse perinatal outcome. In contrast, multiparous gravidae, who should be at lower risk of adverse pregnancy outcomes, actually had increased PE, post-dated pregnancies, neonatal death and total perinatal mortality. Therefore, our results indicated that rubella seronegative status in our multiparous gravidae plays proxy for subtle alteration in maternal immune response which increases occurrence of PE. Both increased PE and post-dated pregnancy had probably contributed to the increased perinatal and neonatal deaths, despite our policy of labour induction before 42 weeks gestation, as a gestation extending to 41 weeks and beyond is by itself associated with increased foetal hypoxia, antepartum and intrapartum foetal distress and acidosis, and intrauterine, neonatal and total perinatal deaths31–33, even though rubella sero-negativity has not been identified as a risk factor for prolonged and post-dated pregnancy34,35.

Our findings were at variance with the aforementioned case–control study that reported no effect of rubella sero-negativity on pregnancy outcome11 and pointed to the need for an adequate sample size in order to confirm or exclude an association with adverse pregnancy outcomes which may not be too frequent. The strengths of our study are the large size of the cohort which was ethnically homogenous, the uniform approach in clinical management and data collection for the generation of annual audits and statistical reports the accuracy of which has been validated previously10, the routine screening for rubella serology by accredited central laboratories using standard protocols and tests, and all being under a diligently carried out health policy of universal plus

| Rubella status |  |  |  |  |
|----------------|-------------|-------------|-------|-------|
| Medical history |  |  |  |  |
| Seronegative | 10.6 | 12.7 | $< 0.001$ | 0.837 (0.795–0.881) |
| Chronic hypertension | 0.4 | 0.4 | 0.609 | 0.933 (0.744–1.219) |
| Pre-gestational diabetes | 0.4 | 0.3 | 0.096 | 1.269 (0.962–1.674) |
| Autoimmune disorders | 0.4 | 0.3 | 0.620 | 1.070 (0.819–1.399) |
| Abortion history | 49.1 | 43.9 | $< 0.001$ | 1.119 (1.098–1.140) |
| Previous cesarean delivery | 18.8 | 16.9 | $< 0.001$ | 1.109 (1.047–1.174) |
| Obstetric complications | 21.7 | 20.4 | 0.021 | 1.061 (1.009–1.115) |
| Gestational hypertension | 1.1 | 1.4 | 0.008 | 0.794 (0.670–0.941) |
| Pre-eclampsia | 1.7 | 1.4 | 0.018 | 1.185 (1.030–1.362) |
| Gestational diabetes | 8.5 | 8.1 | 0.171 | 1.042 (0.982–1.106) |
| Placental abruption | 1.1 | 1.1 | 0.307 | 1.091 (0.923–1.289) |
| Placenta praevia | 1.0 | 1.0 | 0.689 | 1.013 (0.846–1.213) |
| Preterm birth <37 weeks | 6.6 | 6.4 | 0.446 | 1.027 (0.960–1.098) |
| Post-dated pregnancy | 1.6 | 0.9 | $< 0.001$ | 1.669 (1.442–1.930) |
| Labour induction | 22.0 | 22.9 | 0.017 | 0.960 (0.928–0.993) |
| Instrumental vaginal delivery | 12.3 | 13.1 | 0.036 | 0.938 (0.884–0.996) |
| Caesarean section | 23.3 | 22.0 | 0.001 | 1.059 (1.025–1.094) |
| Manual removal of placenta | 4.1 | 3.6 | 0.002 | 1.145 (1.049–1.248) |
| Postpartum haemorrhage | 3.1 | 3.4 | 0.088 | 0.918 (0.831–1.013) |
| Infant ≥ 4000 g | 3.7 | 2.9 | $< 0.001$ | 1.286 (1.172–1.411) |
| Infant < 2500 g | 6.4 | 6.6 | 0.301 | 0.965 (0.901–1.033) |
| Male infant | 52.5 | 52.0 | 0.358 | 1.008 (0.991–1.025) |
| Apgar score <7 at 5th min | 0.6 | 0.5 | 0.340 | 1.124 (0.884–1.434) |
| Perinatal mortality | 0.5 | 0.4 | 0.077 | 1.273 (0.974–1.663) |
| Stillbirth | 0.3 | 0.2 | 0.436 | 1.143 (0.816–1.603) |
| Neonatal death | 0.2 | 0.1 | 0.045 | 1.566 (1.006–2.437) |

Table 2. Obstetric outcome between rubella seronegative (n = 13,320) versus seropositive (n = 120,606) gravidae. Significant differences shown in bold. Results in %, analysis with chi square test and relative risk (RR) and 95% confidence intervals (CI). *Denotes analysis among multiparous gravidae.
Table 3. Obstetric outcome between rubella seronegative (n = 6363) versus seropositive (n = 62,669) nulliparous gravidae. Significant differences shown in bold. Results in %, analysis with chi square test and relative risk (RR) and 95% confidence intervals (CI).

| Rubella status                  | Seronegative | Seropositive | p     | RR (95% CI)                |
|---------------------------------|--------------|--------------|-------|----------------------------|
| Medical history (%)             | 10.9         | 12.9         | < 0.001 | 0.847 (0.787–0.911)        |
| Abortion history (%)            | 40.4         | 37.5         | < 0.001 | 1.076 (1.043–1.111)        |
| Obstetric complications (%)     | 20.7         | 18.8         | 0.015  | 1.096 (1.018–1.180)        |
| Gestational hypertension       | 1.3          | 1.7          | 0.023  | 0.772 (0.617–0.966)        |
| Pre-eclampsia                   | 2.0          | 1.8          | 0.268  | 1.109 (0.924–1.332)        |
| Gestational diabetes            | 6.2          | 6.7          | 0.198  | 0.937 (0.848–1.035)        |
| Placental abruption             | 1.2          | 1.1          | 0.390  | 1.107 (0.878–1.395)        |
| Placenta praevia                | 0.8          | 0.8          | 0.645  | 0.934 (0.700–1.247)        |
| Preterm birth <37 weeks         | 6.5          | 6.6          | 0.699  | 0.981 (0.889–1.082)        |
| Post-dated pregnancy            | 1.7          | 0.9          | < 0.001 | 1.900 (1.550–2.329)        |
| Labour induction                | 27.3         | 28.6         | 0.037  | 0.957 (0.917–0.998)        |
| Instrumental vaginal delivery   | 20.6         | 20.6         | 0.971  | 1.001 (0.939–1.068)        |
| Caesarean section               | 23.6         | 22.9         | 0.216  | 1.030 (0.983–1.079)        |
| Manual removal of placenta      | 4.9          | 3.8          | < 0.001 | 1.270 (1.132–1.426)        |
| Postpartum haemorrhage          | 3.2          | 3.6          | 0.080  | 0.881 (0.764–1.015)        |
| Infant ≥4000 g                  | 2.7          | 2.0          | < 0.001 | 1.344 (1.147–1.574)        |
| Infant <2500 g                  | 7.2          | 7.7          | 0.150  | 0.934 (0.852–1.025)        |
| Male infant                     | 51.1         | 51.7         | 0.346  | 0.988 (0.963–1.013)        |
| Apgar score <7 at 5th min       | 0.5          | 0.6          | 0.532  | 0.893 (0.626–1.274)        |
| Perinatal mortality             | 0.4          | 0.4          | 0.491  | 0.861 (0.563–1.318)        |
| Stillbirth                      | 0.2          | 0.3          | 0.261  | 0.733 (0.426–1.262)        |
| Neonatal death                  | 0.1          | 0.1          | 0.635  | 1.182 (0.592–2.359)        |

Table 4. Obstetric outcome between rubella seronegative (n = 6957) versus seropositive (n = 57,937) multiparous gravidae. Significant differences shown in bold. Results in %, analysis with chi square test and relative risk (95% confidence intervals).

| Rubella status                  | Seronegative | Seropositive | p     | RR (95% CI)                |
|---------------------------------|--------------|--------------|-------|----------------------------|
| Medical history (%)             | 10.4         | 12.5         | < 0.001 | 0.830 (0.772–0.892)        |
| Abortion history (%)            | 57.1         | 50.8         | < 0.001 | 1.124 (1.100–1.149)        |
| Obstetric complications (%)     | 22.6         | 22.1         | 0.480  | 1.025 (0.958–1.097)        |
| Gestational hypertension       | 0.9          | 1.0          | 0.273  | 0.865 (0.667–1.122)        |
| Pre-eclampsia                   | 1.4          | 1.0          | 0.003  | 1.388 (1.117–1.724)        |
| Gestational diabetes            | 10.5         | 9.7          | 0.034  | 1.082 (1.006–1.164)        |
| Placental abruption             | 1.1          | 1.0          | 0.498  | 1.087 (0.854–1.383)        |
| Placenta praevia                | 1.1          | 1.1          | 0.684  | 1.049 (0.838–1.322)        |
| Preterm birth <37 weeks         | 6.7          | 6.2          | 0.121  | 1.077 (0.981–1.183)        |
| Post-dated pregnancy            | 1.5          | 1.0          | < 0.001 | 1.465 (1.188–1.805)        |
| Labour induction                | 17.1         | 16.8         | 0.483  | 1.020 (0.965–1.077)        |
| Instrumental vaginal delivery   | 5.1          | 5.2          | 0.694  | 0.974 (0.852–1.113)        |
| Caesarean section               | 23.1         | 22.1         | < 0.001 | 1.096 (1.047–1.147)        |
| Manual removal of placenta      | 3.4          | 3.4          | 0.702  | 1.026 (0.899–1.171)        |
| Postpartum haemorrhage          | 3.1          | 3.2          | 0.386  | 0.962 (0.838–1.109)        |
| Infant ≥4000 g                  | 4.6          | 3.8          | < 0.001 | 1.209 (1.079–1.355)        |
| Infant <2500 g                  | 5.6          | 5.4          | 0.313  | 1.035 (0.934–1.146)        |
| Male infant                     | 53.7         | 52.4         | 0.039  | 1.025 (1.002–1.049)        |
| Apgar score <7 at 5th min       | 0.6          | 0.4          | 0.021  | 1.472 (1.057–2.050)        |
| Perinatal mortality             | 0.5          | 0.3          | < 0.001 | 1.851 (1.303–2.628)        |
| Stillbirth                      | 0.3          | 0.2          | 0.010  | 1.769 (1.139–2.746)        |
| Neonatal death                  | 0.2          | 0.1          | 0.017  | 2.010 (1.122–3.601)        |
Vaccination induces a marked increase in IL-4 and IL-10 levels. One of the immunological features of PE is probably related to different maternal immunological and cytokine profiles. Among vaccine responders, rubella vaccination improves the regulation of the immune regulatory system. It is therefore possible that different cytokine profiles and alterations in the circulating cytokines from Th2 to predominantly Th1 profile and a down-regulation of the innate immune response are involved in this association.

The data is the property of the hospital and the Hospital Authority, request for access should be made to the hospital through our department. The data is available in an open-access database. The limitations of this study are the lack of detailed information on the individual cases with adverse outcomes, especially the cases of perinatal death. As well, the risk of stillbirth is gestational age-related, being similar between expectant management and delivery at 38 weeks gestation, but then increases progressively despite improvement in perinatal care over the years. As well, the risk of stillbirth is gestational age-related, being similar between expectant management and delivery at 38 weeks gestation, but then increases progressively despite improvement in perinatal care over the years. As well, the risk of stillbirth is gestational age-related, being similar between expectant management and delivery at 38 weeks gestation, but then increases progressively despite improvement in perinatal care over the years. As well, the risk of stillbirth is gestational age-related, being similar between expectant management and delivery at 38 weeks gestation, but then increases progressively despite improvement in perinatal care over the years. As well, the risk of stillbirth is gestational age-related, being similar between expectant management and delivery at 38 weeks gestation, but then increases progressively despite improvement in perinatal care over the years.

Table 5. Multiple logistic regression analysis of the independent association between rubella seronegativity with specific pregnancy outcomes. Significant differences shown in bold. Results expressed in adjusted relative risk (aRR) and 95% confidence intervals (CI). aAdjusted for age ≥ 35 years, body mass index ≥ 25 kg/m2, height ≤ 154 cm, infant gender = male, previous abortion history, any medical history. bAdjusted for obstetric complications including hypertensive disorders and gestational diabetes in addition to.

| Outcome                          | Whole cohort | Nulliparas | Multiparas |
|----------------------------------|--------------|------------|------------|
| Any obstetric complicationa      | 1.049 (0.982–1.120) | 1.074 (0.977–1.181) | 1.020 (0.931–1.116) |
| Gestational diabetesa            | 0.947 (0.886–1.013) | 0.850 (0.762–0.950) | 1.014 (0.931–1.103) |
| Gestational hypertensiona        | 0.757 (0.637–0.900) | 0.714 (0.567–0.899) | 0.818 (0.628–1.066) |
| Pre-eclampsiaa                   | 1.142 (0.987–1.321) | 1.066 (0.881–1.289) | 1.261 (1.005–1.582) |
| Preterm birthb                   | 1.007 (0.935–1.085) | 0.874 (0.744–1.028) | 0.995 (0.850–1.164) |
| Pregnancy > 41 weeksb            | 1.411 (1.201–1.658) | 1.492 (1.194–1.865) | 1.323 (1.046–1.674) |
| Labour inductiona                | 1.011 (0.942–1.084) | 0.964 (0.878–1.059) | 1.066 (0.958–1.185) |
| Caesarean sectiona               | 0.995 (0.931–1.063) | 0.933 (0.852–1.022) | 1.063 (0.965–1.171) |
| Manual removal of placentaa      | 0.944 (0.848–1.052) | 0.987 (0.854–1.140) | 0.892 (0.759–1.049) |
| Postpartum haemorrhagea          | 0.827 (0.703–0.973) | 0.816 (0.646–1.032) | 0.840 (0.670–1.053) |
| Infant ≥ 4000gb                   | 1.107 (0.908–1.267) | 1.182 (0.946–1.476) | 1.070 (0.904–1.266) |
| Apgar score < 7 at 5th mina       | 1.181 (0.861–1.620) | 1.053 (0.698–1.592) | 1.383 (0.846–2.261) |
| Perinatal deatha                 | 1.443 (0.987–2.108) | 1.005 (0.574–1.760) | 2.123 (1.257–3.587) |
| Stillbirtha                      | 1.144 (0.696–1.881) | 0.772 (0.372–1.602) | 1.779 (0.881–3.549) |
| Neonatal deathb                  | 2.154 (1.190–3.899) | 1.677 (0.693–4.056) | 2.796 (1.243–6.291) |

Data availability

The data is the property of the hospital and the Hospital Authority, request for access should be made to the hospital through our department.
References

1. Banatvala, J. E. & Brown, D. W. G. Rubella, Lancet 363, 1127–1137 (2004).
2. Davidkin, I., Peltola, H. & Leinikki, P. Epidemiology of rubella in Finland. Euro Surveill. 9, 13–14 (2004).
3. Francis, B. H., Thomas, A. K. & McCarty, C. A. The impact of rubella immunization on the serological status of women of child-bearing age: A retrospective longitudinal study in Melbourne, Australia. Am. J. Public Health 93, 1274–1276 (2003).
4. Bascom, S., Miller, S. & Greenblatt, J. Assessment of perinatal hepatitis B and rubella prevention in New Hampshire Delivery Hospitals. Pediatrics 115, e594–e599 (2005).
5. Iseng, H.-E., Chang, C.-K., Tan, H.-E., Yang, S.-E. & Chang, H.-W. Seroepidemiology study of rubella antibodies among pregnant women from seven Asian countries: Evaluation of the rubella vaccination program in Taiwan. Vaccine 24, 5772–5777 (2006).
6. Pebody, R. G. et al. The seroepidemiology of rubella in Western Europe. Epidemiol. Infect. 125, 347–357 (2000).
7. Nardone, A. et al. Comparison of rubella seroepidemiology in 17 countries: Progress towards international disease control targets. Bull. World Health Organ. 86, 118–125 (2008).
8. Department of Health, Hong Kong. Rubella in Hong Kong. Public Health and Epidemiology Bulletin 4:17–20 (1995).
9. Chuang, S. K. et al. Mass measles immunization campaign: Experience in the Hong Kong Special Administrative Region of China. Bull. World Health Organ. 80, 585–591 (2002).
10. Lao, T. T., Suen, S. S., Leung, T. Y., Sahota, D. S. & Lau, T. K. Universal rubella vaccination programme and maternal rubella immune status: A tale of two systems. Vaccine 28, 2227–2230 (2010).
11. Schwartzenburg, C. J., Gilmandyar, D., Thornburg, L. L. & Hackney, D. N. Pregnancy outcomes of women with failure to retain rubella immunity. J. Matern. Fetal. Neonatal Med. 27, 1845–1848 (2014).
12. Lao, T. T., Sahota, D. S., Law, L. W. & Leung, T. Y. Maternal rubella immunity status and pre-eclampsia. Am. J. Reprod. Immunol. https://doi.org/10.1111/aji.12677 (2017).
13. Marzi, M. et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin. Exp. Immunol. 106, 127–133 (1996).
14. Raghupathy, R. et al. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum. Reprod. 15, 713–718 (2000).
15. Mor, G. & Cardenas, I. The immune system in pregnancy: A unique complexity. Am. J. Reprod. Immunol. 63, 425–433 (2010).
16. Arziah, F. et al. Multivariate analysis of cytokine profiles in pregnancy complications. J. Reprod. Immunol. 79, e12818 (2018).
17. Duckitt, K. & Harrington, D. Risk factors for pre-eclampsia at antenatal booking: Systematic review of controlled studies. Br. Med. J. 330, 565. https://doi.org/10.1136/bmj.38380.674340.E0 (2005).
18. Chan, B. C. P. & Lao, T. T. H. Effect of parity and advanced maternal age on obstetric outcome. Int. J. Gynecol. Obstet. 102, 237–241 (2008).
19. Wang, Y., Tanbo, T., Åbyholm, T. & Henriksen, T. The impact of advanced maternal age and parity on obstetric and perinatal outcomes in singleton gestations. Arch. Gynecol. Obstet. 284, 31–37 (2011).
20. Lao, T. T., Hui, A. S. Y., Sahota, D. S. & Leung, T. Y. Maternal height and risk of hypertensive disorders in pregnancy. J. Matern. Fetal. Neonatal Med. 32, 1420–1425 (2019).
21. Shierer, E., Levy, A., Katz, M. & Mazor, M. Pregnancy outcome following recurrent spontaneous abortions. Eur. J. Obstet. Gynecol. Reprod. Biol. 118, 61–65 (2005).
22. Weisz, A. Y. et al. An initial miscarriage is associated with adverse pregnancy outcomes in the following pregnancy. Am. J. Obstet. Gynecol. 205(286), e1–e5 (2011).
23. Gannudstorp, J., Stephansson, O., Cnattingius, S., Åkerud, H. & Wikström, A.-K. Risk of placental dysfunction disorders after prior miscarriages: A population-based study. Am. J. Obstet. Gynecol. 211, 34.e1–e8 (2014).
24. Oliver-Williams, C., Fleming, M., Wood, A. M. & Smith, G. C. S. Previous miscarriage and the subsequent risk of preterm birth in Scotland, 1980–2008: A historical cohort study. Br. J. Obstet. Gynaecol. 122, 1525–1534 (2015).
25. Hiersch, L. et al. The association between previous single first trimester abortion and pregnancy outcome in nulliparous women. J. Matern. Fetal. Neonatal Med. 29, 1457–1461 (2016).
26. Lao, T. T., Hui, A. S. Y., Leung, L. W. & Sahota, D. S. Prior abortion history and pregnancy hypertensive disorders in primiparous gravidas. Preg. Hypertens. 14, 168–173 (2018).
27. Elezmin, E., Källén, K., Marsål, K. & Hellström-Westas, L. Fetal gender and gestational-age-related incidence of pre-eclampsia. Acta Obstet. Gynecol. Scand. 85, 1285–1291 (2006).
28. Brown, M. A. et al. Hypertensive disorders of pregnancy. ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 72, 24–43 (2018).
29. Melamed, N., Ray, J. G., Hladunewich, M., Cox, B. & Kingdom, J. C. Gestational hypertension and preeclampsia: Are they the same disease?. J. Obstet. Gynaecol. Can. 36, 642–647 (2014).
30. Bai, J., Wong, F. W. S., Bauman, A. & Mohsin, M. Parity and pregnancy outcome. Am. J. Obstet. Gynecol. 186, 274–278 (2002).
31. Ayyavoo, A., Derraik, J. G. B., Hofman, P. L. & Cutfield, W. S. Postterm births: Are prolonged pregnancies too long?. J. Pediatr. 164, 647–651 (2014).
32. Kortekaas, J. C. et al. Perinatal death beyond 41 weeks pregnancy: An evaluation of causes and substandard care factors as identified in perinatal audit in the Netherlands. BMC Pregnancy Childbirth 18, 380. https://doi.org/10.1186/s12884-018-1973-z (2018).
33. Mugla, J. et al. Risks of stillbirth and neonatal death with advancing gestation at term: A systematic review and meta-analysis of cohort studies of 15 million pregnancies. PLoS Med. 16(7), e1002838. https://doi.org/10.1371/journal.pmed.1002838 (2019).
34. Caughley, A. B., Stotland, N. E., Washington, A. E. & Escobar, G. J. Who is at risk for prolonged and postterm pregnancy?. Am. J. Obstet. Gynecol. 200, 683.e1–683.e5 (2009).
35. Roos, N., Sahlin, L., Ekman-Ordeberg, G., Kieler, H. & Stephansson, O. Maternal risk factors for postterm pregnancy and caesarean delivery following labor induction. Acta Obstet. Gynecol. Scand. 89, 1003–1010 (2010).
36. Branum, A. M. & Schoenfeld, K. C. The influence of maternal age on very preterm birth of twins: Differential effects by parity. Paediatr. Perinat. Epidemiol. 19, 399–404 (2005).
37. Gardosi, J., Clausson, B. & Francis, A. The value of customised centiles in assessing perinatal mortality risk associated with parity and maternal size. Br. J. Obstet. Gynaecol. 116, 1356–1363 (2009).
38. Gardosi, J., Madarasinghe, V., Williams, M., Malik, A. & Francis, A. Maternal and fetal risk factors for stillbirth: Population based study. Br. Med. J. https://doi.org/10.1136/bmj.f1108 (2013).
39. Pukhalsky, A. L. et al. Cytokine profile after rubella vaccine inoculation: Evidence of the immunosuppressive effect of vaccination. Mediators Inflamm. 12, 203–207 (2003).
40. Jonsson, Y. et al. Indications of an altered immune balance in preeclampsia: A decrease in vitro secretion of IL-5 and IL-10 from blood mononuclear cells and in blood basophil counts compared with normal pregnancy. J. Reprod. Immunol. 66, 69–84 (2005).
41. Chatterjee, P. et al. Interleukin-4 deficiency induces mild preeclampsia in mice. J. Hypertens. 31, 1414–1423 (2013).
42. Dekker, G. & Robillard, P.-Y. Pre-eclampsia: Is the immune maladaptation hypothesis still standing? An epidemiological update. J. Reprod. Immunol. 76, 8–16 (2007).
43. Jonsson, Y. et al. Cytokine mapping of sera from women with preeclampsia and normal pregnancies. J. Reprod. Immunol. 70, 83–91 (2006).
44. Saito, S., Shiozaki, A., Nakashima, A., Sakai, M. & Sasaki, Y. The role of the immune system in preeclampsia. Mol. Aspects Med. 28, 192–209 (2007).
45. Lareggoiti-Servitje, E., Gómez-López, N. & Olson, D. M. An immunological insight into the origins of pre-eclampsia. Hum. Reprod. Update 16, 510–524 (2010).
46. Pinheiro, M. B. et al. Severe preeclampsia goes along with a cytokine network disturbance towards a systemic inflammatory state. Cytokine 62, 165–173 (2013).
47. Harmon, Q. E. et al. Risk of fetal death with preeclampsia. Obstet. Gynecol. 125, 628–635 (2015).
48. Basso, O. et al. Trends in fetal and infant survival following preeclampsia. JAMA 296, 1357–1362 (2006).
49. Rosenstein, M. G., Cheng, Y. W., Snowden, J. M., Nicholson, J. M. & Caughey, A. B. Risk of stillbirth and infant death stratified by gestational age. Obstet. Gynecol. 120, 76–82 (2012).

Author contributions
T.T.L. conceived the study, analysed and interpreted the data, and wrote the manuscript. S.Y.A.H. contributed to the design, obtained ethical approval, helped in data interpretation, and preparation of the manuscript. D.S.S. set up the database, contributed to the design, data analysis and interpretation, and final preparation of the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to T.T.L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022